Qynapse

Company Overview

Qynapse aims to brings groundbreaking technology to the global fight against Central Nervous System (CNS) disorders. Founded in Paris, France in 2015, as a spin-off from the CATI consortium of neuroimaging research laboratories, Qynapse is on a mission to advance the accuracy and reliability of CNS disease screening and monitoring in both clinical routine settings and in clinical trial applications with its quantitative solutions.

The company is Headquartered in France, and with offices in the United States and in Canada. Qynapse's team of scientific and clinical partners is dedicated to bring the neuroscience community and their patients the most accurate and reliable predictors and objective measures of devastating CNS disorders such as Alzheimer’s disease, Multiple Sclerosis and Parkinson’s disease. They envision a brighter and more precise future of diagnosis and treatment for CNS diseases. 

Modalities